Lysosomal Therapeutics Financing
Lysosomal Therapeutics, Inc., Corporation just submitted form D regarding $6.00 million debt financing. This is a new filing. Lysosomal Therapeutics was able to fundraise $6.00 million. That is 100.00% of the fundraising. The total financing amount was $6.00 million. The financing document was filed on 2016-10-05. The reason for the financing was: unspecified.
Lysosomal Therapeutics is based in Massachusetts. The firm’s business is Biotechnology. The form was signed by Cornelis Been President & CEO. The company was incorporated in 2011. The filler’s address is: 19 Blackstone Street, Cambridge, Ma, Massachusetts, 02139. Cornelis Been is the related person in the form and it has address: C/O Lysosomal Therapeutics, Inc., 19 Blackstone Street, Cambridge, Ma, Massachusetts, 02139. Link to Lysosomal Therapeutics Filing: 000160785416000003.
Analysis of Lysosomal Therapeutics Offering
On average, firms in the Biotechnology sector, sell 73.77% of the total offering size. Lysosomal Therapeutics sold 100.00% of the offering. Could this mean that the trust in Lysosomal Therapeutics is high? The average financing size for companies in the Biotechnology industry is $3.08 million. The total amount raised is 94.81% bigger than the average for companies in the Biotechnology sector. The minimum investment for this fundraising is set at $0. If you know more about the reasons for the financing, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Lysosomal Therapeutics Also
The Form D signed by Cornelis Been might help Lysosomal Therapeutics, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.